{
    "organizations": [],
    "uuid": "68232b7ffd86f2c333b75116bce0d0f01e5ce6b9",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/02/27/globe-newswire-regenxbio-to-host-conference-call-on-march-6-to-discuss-fourth-quarter-and-full-year-2017-financial-results-and-recent.html",
    "ord_in_thread": 0,
    "title": "REGENXBIO to Host Conference Call on March 6 to Discuss and Financial and Recent Operational Highlights",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "ROCKVILLE, Md., Feb. 27, 2018 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Tuesday, March 6, 2018 at 4:30 p.m. ET to discuss its financial results for the quarter and full year ended December 31, 2017 and recent operational highlights.\nTo access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international), and enter the passcode 1584469. To access a live or recorded webcast of the call, please visit the “Investors” section of the REGENXBIO website at www.regenxbio.com . The recorded webcast will be available for approximately 30 days following the call.\nAbout REGENXBIO Inc.\nREGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.\nCONTACT:\nInvestors\nNatalie Wildenradt, 646-681-8192\nnatalie@argotpartners.com\nMedia\nAdam Pawluk, 202-591-4063\napawluk@jpa.com\nSource:REGENXBIO Inc.",
    "published": "2018-02-28T00:05:00.000+02:00",
    "crawled": "2018-02-28T02:11:33.002+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "rockville",
        "globe",
        "newswire",
        "regenxbio",
        "nasdaq",
        "rgnx",
        "leading",
        "biotechnology",
        "company",
        "seeking",
        "improve",
        "life",
        "curative",
        "potential",
        "gene",
        "therapy",
        "based",
        "proprietary",
        "technology",
        "platform",
        "today",
        "announced",
        "host",
        "conference",
        "call",
        "tuesday",
        "march",
        "et",
        "discus",
        "financial",
        "result",
        "quarter",
        "full",
        "year",
        "ended",
        "december",
        "recent",
        "operational",
        "highlight",
        "access",
        "live",
        "call",
        "phone",
        "dial",
        "domestic",
        "international",
        "enter",
        "passcode",
        "access",
        "live",
        "recorded",
        "webcast",
        "call",
        "please",
        "visit",
        "investor",
        "section",
        "regenxbio",
        "website",
        "recorded",
        "webcast",
        "available",
        "approximately",
        "day",
        "following",
        "call",
        "regenxbio",
        "regenxbio",
        "leading",
        "biotechnology",
        "company",
        "seeking",
        "improve",
        "life",
        "curative",
        "potential",
        "gene",
        "therapy",
        "regenxbio",
        "technology",
        "platform",
        "proprietary",
        "virus",
        "aav",
        "gene",
        "delivery",
        "platform",
        "consists",
        "exclusive",
        "right",
        "novel",
        "aav",
        "vector",
        "including",
        "aav7",
        "aav8",
        "aav9",
        "aavrh10",
        "regenxbio",
        "nav",
        "technology",
        "platform",
        "licensee",
        "applying",
        "nav",
        "technology",
        "platform",
        "development",
        "broad",
        "pipeline",
        "candidate",
        "multiple",
        "therapeutic",
        "area",
        "contact",
        "investor",
        "natalie",
        "wildenradt",
        "natalie",
        "medium",
        "adam",
        "pawluk",
        "apawluk",
        "source",
        "regenxbio",
        "inc"
    ]
}